Earnings Call Summary | Cryoport(CYRX.US) Q1 2024 Earnings Conference
Earnings Call Summary | Cryoport(CYRX.US) Q1 2024 Earnings Conference
The following is a summary of the Cryoport, Inc. (CYRX) Q1 2024 Earnings Call Transcript:
以下是Cryoport, Inc.（CYRX）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Cryoport ended Q1 2024 with disappointing results but maintains its annual revenue guidance of $242 to $252 million.
First-quarter commercial therapies and BioStorage/BioServices revenue both grew by 9%.
Revenue growth from life sciences services increased by 3% year-over-year.
The company ended the quarter with a cash balance of $448,500,000, but reported over $8 million in cash burn in Q1, with over $4 million specific to CapEx expenses.
EBITDA loss was reported at $7.7 million, yet the company aims for long-term gross margins of 55% to 60%.
Biologistics and BioStorage needs are expected to grow following an uptick in life sciences consumables.
Cryoport在2024年第一季度結束時業績令人失望，但其年度收入預期維持在2.42億美元至2.52億美元。
第一季度商業療法和生物存儲/生物服務收入均增長了9％。
生命科學服務的收入同比增長3％。
該公司在本季度末的現金餘額爲4.485億美元，但報告第一季度現金消耗超過800萬美元，其中超過400萬美元專用於資本支出。
據報道，息稅折舊攤銷前利潤虧損爲770萬美元，但該公司的目標是將長期毛利率定爲55％至60％。
隨着生命科學消耗品的增加，生物學和生物存儲需求預計將增長。
Business Progress:
業務進展：
The company saw a rise in the number of supported global clinical trials to 675, providing a prospective opportunity for long-term revenue growth.
Cryoport is implementing initiatives to improve adjusted EBITDA and cash flow; these include workforce reduction, using lower-cost shared services, and refining and reprioritizing initiatives.
The future seems promising with the expectation of five new therapy approvals and three additional label or geographic expansions.
The company is preparing to arrange supply chain support for cell and gene therapies in the life sciences.
Manufacturing plans in China are active and are expected to begin production by mid-next year.
The company has completed various acquisitions and is streamlining its operations.
Cryoport is set to roll out IntegriCell in the second half of the year, which is expected to generate substantial revenues.
The company continues to focus on maintaining a strong balance sheet and operational capabilities, expecting to progress throughout the year despite difficult market conditions.
該公司支持的全球臨床試驗數量增加到675項，爲長期收入增長提供了前景機會。
Cryoport正在實施改善調整後的息稅折舊攤銷前利潤和現金流的舉措；其中包括裁員、使用較低成本的共享服務以及完善和重新確定舉措的優先順序。
未來似乎充滿希望，預計將有五種新療法獲得批准，另有三項標籤或地域擴張。
該公司正準備爲生命科學領域的細胞和基因療法安排供應鏈支持。
中國的製造計劃正在進行中，預計將於明年年中開始生產。
該公司已經完成了各種收購，並正在精簡其運營。
Cryoport定於下半年推出IntegriCell，預計這將產生可觀的收入。
該公司繼續專注於保持強勁的資產負債表和運營能力，儘管市場條件艱難，預計全年仍將取得進展。
More details: Cryoport IR
更多詳情： Cryoport IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。